Skip to main content
Premium Trial:

Request an Annual Quote

Scotland Launches Biopark with Donated MSD Labs

NEW YORK (GenomeWeb News) – The Scottish central lowland region has boosted its available space for hosting life sciences companies after MSD, which operates in the US and Canada as Merck, donated a research facility to house BioCity Scotland, a joint life sciences biopark and incubator venture run by BioCity Nottingham and the Roslin BioCentre.

Located between Glasgow and Edinburgh, the facility in Newhouse, Lanarkshire will provide over 130,000 square feet of labs on a 23 acre site that will house and support bioscience, pharmaceutical, medical technology, and healthcare companies.

BioCity Scotland provides research and development facilities, including processing, storage, equipment, business, and financial support to start-up companies.

"BioCity Scotland is much more than a property proposition — it will be a unique, vibrant community of scientific companies," BioCity Scotland Chairman Louis Nisbet said in a statement.

"The ongoing commercial operation of the site will attract investment to the local area generating employment opportunities for local communities and the success of this development will play a significant role in securing the future of Life Sciences in Scotland," added Chris Hill, MSD VP and former head of the MSD Newhouse facility.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.